The Role of SGLT 2 Inhibitor in the Therapy of Obesity
Published: 2023-07-09
Page: 104-114
Issue: 2023 - Volume 6 [Issue 1]
Giovanno Sebastian Yogie *
Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia.
Darren Gosal
Faculty of Medicine, Hasanuddin University, Makasar, Indonesia.
Yohanes Firmansyah
Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia.
Alexander Halim Santoso
Department of Clinical Nutrition, Tarumanagara University, Jakarta, Indonesia.
*Author to whom correspondence should be addressed.
Abstract
Obesity is an abnormal or excessive fat accumulation that presents a risk to health, including hypertension, stroke, kidney disease, atherosclerosis, type 2 diabetes mellitus, heart disease, and sleep apnea. Obesity can be caused by various aetiology, such as genetics, lifestyle, psychology, treatment, and more. Treatment of obesity is needed to prevent these further complications. According to various studies, SGLT 2 inhibitor has shown effectiveness in losing weight. This review article aims to describe the effectiveness and safety of SGLT 2 inhibitors in the treatment of obesity. It is expected SGLT 2 inhibitor can be considered in the administration of therapy in patients with obesity.
Keywords: Obesity, SGLT 2 inhibitor, weight loss
How to Cite
Downloads
References
Purnell J. Definitions, Classification, and Epidemiology of Obesity. South Dartmouth: Endotext; 2018.
Lim JU, Lee JH, Kim JS, Hwang Y Il, Kim TH, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J COPD 2017;12:2465–75. Available:https://doi.org/10.2147/COPD.S1 41295
Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract 2017;29:S3–14. Available:https://doi.org/10.1002/2327- 6924.12510.
Lam BC, Lim AL, Chan S, Yum MS, Koh NY, Finkelstein E. The impact of obesity: a narrative review. Singapore Med J 2023;64:163. Available:https://doi.org/10.4103/singapore medj.smj-2022-232.
WHO. Obesity and overweight. World Heal Organ; 2021.
Kementerian Kesehatan RI. Laporan Riskesdas 2018. Lemb Penerbit Balitbangkes; 2018.
Thaker V V. Genetic And Epigenetic Causes Of Obesity. Adolesc Med State Art Rev. 2017;28:379–405.
Funcke J-B, von Schnurbein J, Lennerz B, Lahr G, Debatin K-M, Fischer-Posovszky P, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol Cell Pediatr. 2014;1:1–8. Available:https://doi.org/10.1186/s40348- 014-0003-1.
Nunziata A, Funcke JB, Borck G, Von Schnurbein J, Brandt S, Lennerz B, et al. Functional and Phenotypic Characteristics of Human Leptin Receptor Mutations. J Endocr Soc. 2019;3:27–41. Available:https://doi.org/10.1210/js.2018- 00123.
Hilado MA, Randhawa RS. A novel mutation in the proopiomelanocortin (POMC) gene of a Hispanic child: Metformin treatment shows a beneficial impact on the body mass index. J Pediatr Endocrinol Metab. 2018;31: 815–9. Available:https://doi.org/10.1515/jpem- 2017-0467.
Burnett LC, Leduc CA, Sulsona CR, Paull D, Rausch R, Eddiry S, et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest. 2017;127: 293–305. Available:https://doi.org/10.1172/JCI88648
Kerkadi A, Sadig AH, Bawadi H, Thani AAM Al, Chetachi W Al, Akram H, et al. The relationship between lifestyle factors and obesity indices among adolescents in Qatar. Int J Environ Res Public Health. 2019;16:1–15. Available:https://doi.org/10.3390/ijerph162 24428.
Cha E, Akazawa MK, Kim KH, Dawkins CR, Lerner HM, Umpierrez G, et al. Lifestyle habits and obesity progression in overweight and obese American young adults: Lessons for promoting cardiometabolic health. Nurs Heal Sci. 2015;17:467–75. Available:https://doi.org/10.1111/nhs.1221 8.
Tchernof A, Després JP. Pathophysiology of human visceral obesity: An update. Physiol Rev. 2013;93:359–404. Available:https://doi.org/10.1152/physrev.0 0033.2011.
van der Valk ES, van den Akker ELT, Savas M, Kleinendorst L, Visser JA, Van Haelst MM, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. Obes Rev. 2019;20:795–804. Available:https://doi.org/10.1111/obr.12836
Khanna D, Peltzer C, Kahar P, Parmar MS. Body Mass Index (BMI): A Screening Tool Analysis. Cureus. 2022;14:1–6. Available:https://doi.org/10.7759/cureus.22 119.
Nuttall FQ. Body mass index: Obesity, BMI, and health: A critical review. Nutr Today. 2015;50:117–28. Available:https://doi.org/10.1097/NT.00000 00000000092.
Han TS, Sattar N, Lean M. Assessment of obesity and its clinical implications. Br Med J. 2006;333:695–8.
Shariq OA, Mckenzie TJ. Obesity-related hypertension: A review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9:80–93. Available:https://doi.org/10.21037/gs.2019. 12.03.
Hall JE, Do Carmo JM, Da Silva AA, Wang Z, Hall ME. Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms. Circ Res. 2015;116:991– 1006. Available:https://doi.org/10.1161/CIRCRES AHA.116.305697.
Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes, Metab Syndr Obes. 2014;7:587–91.
Available:https://doi.org/10.2147/DMSO.S6 7400.
Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes, Metab Syndr Obes. 2020;13:3611–6. Available:https://doi.org/10.2147/DMSO.S2 75898.
Johnston LW, Harris SB, Retnakaran R, Giacca A, Liu Z, Bazinet RP, et al. Association of NEFA composition with insulin sensitivity and beta cell function in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort. Diabetologia. 2018;61:821–30. Available:https://doi.org/10.1007/s00125- 017-4534-6.
Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021;11:504–29.
Yoo HJ. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes. 2014;5:357. Available:https://doi.org/10.4239/wjd.v5.i3. 357.
Quiñones-Ossa GA, Lobo C, Garcia- Ballestas E, Florez WA, Moscote-Salazar LR, Agrawal A. Obesity and Stroke: Does the Paradox Apply for Stroke? Neurointervention. 2021;16:9–19. Available:https://doi.org/10.5469/neuroint.2 020.00108
McFarlane SI. Obstructive sleep apnea and obesity: implications for public health. Sleep Med Disord Int J. 2017;1:1–15. Available:https://doi.org/10.15406/smdij.20 17.01.00019.
Kuvat N, Tanriverdi H, Armutcu F. The relationship between obstructive sleep apnea syndrome and obesity: A new perspective on the pathogenesis in terms of organ crosstalk. Clin Respir J. 2020;14:595–604. Available:https://doi.org/10.1111/crj.13175.
Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8:402–24. Available:https://doi.org/10.1159/00044272 1.
Gronda E, Jessup M, Iacoviello M, Palazzuoli A, Napoli C. Glucose metabolism in the kidney: Neurohormonal activation and heart failure development. J Am Heart Assoc. 2020;9:1–11.
Available:https://doi.org/10.1161/JAHA.120.018889.
Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1 , SGLT2 and GLUT2 Online Mendelian Inheritance in Man. Diabetologia. 2018;1:2087–97.
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61:2079–86. Available:https://doi.org/10.1007/s00125- 018-4654-7.
Wright EM. Basic Science for Clinicians SGLT2 Inhibitors : Physiology and Pharmacology. 2021;2:2027–37.
Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, et al. The Sweet Pee Model for Sglt2 Mutation. J Am Soc Nephrol. 2011;22:113–23. Available: https://doi.org/10.1681/ASN.2010080888.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications. Diabet Med. 2010;27:136–42. Available:https://doi.org/10.1111/j.1464- 5491.2009.02894.x.
Seidelmann SB, Feofanova E, Yu B, Franceschini N, Claggett B, Kuokkanen M, et al. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. J Am Coll Cardiol. 2018;72: 1763–73. Available:https://doi.org/10.1016/j.jacc.201 8.07.061.
Ma M, Long Q, Chen F, Zhang T, Lu M, Wang W, et al. Nutrition management of congenital glucose–galactose malabsorption. Medicine (Baltimore). 2019;98:e16828. Available:https://doi.org/10.1097/md.00000 00000016828.
Soelistijo S. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021. Jakarta: 2021.
Tsimihodimos V, Filippas-Ntekouan S, Elisaf M. SGLT1 inhibition: Pros and cons. Eur J Pharmacol. 2018;838: 153–6. Available:https://doi.org/10.1016/j.ejphar.2 018.09.019.
Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017;377:2337–48.
Available:https://doi.org/10.1056/nejmoa17 08337.
Koepsell H. The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther. 2017;170: 148–65. Available:https://doi.org/10.1016/j.pharmth era.2016.10.017.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17:761–72. Available:https://doi.org/10.1038/s41569- 020-0406-8.
Pittampalli S, Upadyayula S, Hema;, Mekala M, Lippmann S. Risks vs Benefits for SGLT2 Inhibitor Medications Health care providers should carefully assess patients with diabetes mellitus before prescribing sodium-glucose Cotransporter 2 Inhibitor Medications and Monitor for Adverse Effects. 2018:45–8.
Janssen JAMJL. New Insights into the Role of Insulin and Hypothalamic-Pituitary- Adrenal (HPA) Axis in the Metabolic Syndrome. Int J Mol Sci. 2022;23. Available:https://doi.org/10.3390/ijms23158 178.
Szekeres Z, Sandor B, Bognar Z, Ramadan FHJ, Palfi A, Bodis B, et al. Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. Int J Mol Sci. 2023;24. Available:https://doi.org/10.3390/ijms24054 405.
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic to Transl Sci. 2020;5:632–44. Available:https://doi.org/10.1016/j.jacbts.20 20.02.004.
Kubota Y, Shimizu W. Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia. 2022;2:287–93.
Available:https://doi.org/10.1016/j.jacasi.20 22.03.009.
Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti- atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med. 2022;9.
Available:https://doi.org/10.3389/fcvm.202 2.1008922.
Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes, Obes Metab. 2019;21:1291–8. Available:https://doi.org/10.1111/dom.1367 0.
Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. Clin J Am Soc Nephrol. 2022;17:663–71 Available:https://doi.org/10.2215/CJN.1148 0821.
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. 2022;79:273. Available:https://doi.org/10.1007/s00018- 022-04289-z
Pratama KG, Tandarto K, Hengky A. Weight Loss Effect of Sodium-Glucose Cotransporter-2 (Sglt2) Inhibitors in Patients With Obesity Without Diabetes: a Systematic Review. Acta Endocrinol (Copenh). 2022;18:216–24.
Available:https://doi.org/10.4183/aeb.2022. 216.
Pan R, Zhang Y, Wang R, Xu Y, Ji H, Zhao Y. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS One. 2022;17:1–13. Available:https://doi.org/10.1371/journal.po ne.0279889.
Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three- arm, active control study. J Diabetes Investig. 2020;11:1612–22. Available:https://doi.org/10.1111/jdi.13279.
Sargeant JA, King JA, Yates T, Redman EL, Bodicoat DH, Chatterjee S, et al. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab 2022;24:1509–21.
Available:https://doi.org/10.1111/dom.1472 1.
Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, et al. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2017;9:586–95. Available:https://doi.org/10.14740/jocmr30 38w
Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–64. Available:https://doi.org/10.2337/dc13- 2762.
Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, et al. Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Sci Rep. 2021;11: 1–5. Available:https://doi.org/10.1038/s41598- 021-03773-z.
Han E, Lee YH, Lee BW, Kang ES, Cha BS. Ipragliflozin additively ameliorates non- alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial. J Clin Med. 2020;9:1–14. Available:https://doi.org/10.3390/jcm90102 59.
Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes, Obes Metab. 2017; 19:49–60.
Available:https://doi.org/10.1111/dom.1277 9
Chua MWJ. High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination. Clin Pract. 2022;12:1–7. Available:https://doi.org/10.3390/CLINPRA CT12010001.
Jayasinghe KNU, Greener VJ, Feher MD. Combining SGLT2 inhibitor and GLP-1 agonist: Exaggerated weight loss in a morbidly obese patient with type 2 diabetes. Br J Diabetes Vasc Dis. 2016;16:138–9. Available:https://doi.org/10.15277/bjd.2016.092.
Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: A randomized clinical trial. Diabetes Care. 2017;40:632–9. Available:https://doi.org/10.2337/dc16- 2427.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18:295–311. Available:https://doi.org/10.1080/14740338.2019.1602116.
Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022;9. Available:https://doi.org/10.3389/fcvm.202 2.1010693.
Zhang L, Tamilia M. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor. Cmaj. 2018;190:E766–8.
Available:https://doi.org/10.1503/cmaj.171 319.